Current Opinion in Infectious Diseases,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Jan. 4, 2024
Purpose
of
review
The
purpose
this
is
to
briefly
summarize
the
challenges
associated
with
treatment
pneumonia
caused
by
carbapenem-resistant
Acinetobacter
baumannii
(CRAB),
discuss
its
carbapenem-resistance,
and
literature
supporting
current
paradigm
therapeutic
options.
Recent
findings
In
a
multicenter,
randomized,
controlled
trial
novel
β-lactam-β-lactamase
inhibitor
sulbactam-durlobactam
was
compared
colistin,
both
in
addition
imipenem-cilastatin.
drug
met
prespecified
criteria
for
noninferiority
28-day
all-cause
mortality
while
demonstrating
higher
clinical
cure
rates
CRAB
pneumonia.
an
international,
double-blind,
placebo
colistin
monotherapy
combined
meropenem.
trial,
combination
therapy
not
superior
drug-resistant
gram-negative
organisms
including
Summary
preeminent
public
health
threat
without
agreed
upon
first
line
strategy.
Historically,
there
have
been
drawbacks
available
modalities
clear
consensus
on
first-line
regimen.
top
priority
continued
development
antimicrobials,
adjuvant
therapies
refinement
strategies.
RSC Advances,
Journal Year:
2024,
Volume and Issue:
14(45), P. 33429 - 33448
Published: Jan. 1, 2024
In
this
review,
we
wish
to
compile
examples
of
chiral
medicines
approved
by
the
FDA
in
years
2022
and
2023
with
an
emphasis
on
their
synthesis
along
information
induction
as
well
enantiomeric
excess.
Journal of Medicinal Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 3, 2025
This
review
is
the
next
installment
of
an
annual
series
that
discusses
synthetic
routes
to
access
28
small
molecule
drugs
were
approved
worldwide
in
2023.
A
brief
description
each
drug's
mechanism
action,
history
its
discovery
and
development,
approaches
published
primary
or
patent
literature
most
likely
used
for
clinical
studies
development
are
included.
Synthetic
chemistry,
convert
complex
intermediates
active
compounds
build
a
new
drug
from
basic
building
block
chemicals,
critical
delivery
treatments
disease
patients.
Pathogens,
Journal Year:
2025,
Volume and Issue:
14(2), P. 168 - 168
Published: Feb. 8, 2025
Antimicrobial
resistance
remains
a
public
health
problem
of
global
concern
with
great
and
financial
burden.
Its
recognition
as
threat
by
political
leadership
has
boosted
the
research
development
new
antibiotics
particularly
novel
combinations
β-lactams/β-lactamase
inhibitors
against
multidrug-resistant
(MDR)
Gram-negative
pathogens,
which
remain
major
in
clinical
practice.
The
incorporation
ceftolozane/tazobactam,
ceftazidime/avibactam,
meropenem/vaborbactam,
imipenem/cilastatin/relebactam
provided
therapeutic
options
treatment
patients
infections
due
to
MDR
pathogens.
Cefiderocol
along
cefepime/enmetazobactam,
avibactam/aztreonam,
sulbactam/durlobactam
have
been
recently
added
these
agents
choices,
for
metallo-β-lactamase
producing
bacteria.
Currently,
many
are
being
studied
their
vitro
activity
both
serine-
metallo-β-lactamases.
However,
only
few
advanced
through
phase
1,
2,
3
trials.
Among
them,
this
article,
we
focus
on
most
promising
cefepime/zidebactam,
cefepime/taniborbactam,
imipenem/cilastatin/funobactam,
currently
under
investigation
European Journal of Clinical Microbiology & Infectious Diseases,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 10, 2025
Abstract
The
carbapenemase-producing
Gram-negative
organisms
represent
an
urgent
clinical
and
public
health
concern,
as
they
have
been
associated
with
increased
mortality
high
dissemination
in
healthcare
settings.
Although
overall
incidence
rates
of
infections
sustained
by
metallo-β-lactamase
(MβL)-producers
remained
lower
than
those
other
carbapenemase-producers,
albeit
substantial
geographic
differences,
a
significant
increase
the
prevalence
MβL-producers
has
observed
over
last
decade.
recent
development
new
antimicrobials
expanded
armamentarium
to
counter
challenge
(MβL)-producers.
Cefiderocol
aztreonam/avibactam
are
already
clinically
available
recommended
international
guidelines.
In
addition,
two
classes
β-lactam/
β-lactamase
combinations
under
evaluation:
(
i
)
combination
β-lactam
novel
boronic-derived
inhibitors
(e.g.
taniborbactam
xeruborbactam),
ii
generation
diazabicyclooctane
zidebactam
nacubactam),
active
on
most
serine-β-lactamases
but
also
showing
strong
intrinsic
activity
PBP-2.
This
review
aims
provide
up-to-date
data
characteristics,
emerging
resistance
mechanisms
or
soon-to-be
introduced
drugs
for
treatment
MβL-producing
organisms.
Antimicrobial Agents and Chemotherapy,
Journal Year:
2024,
Volume and Issue:
68(4)
Published: Feb. 27, 2024
ABSTRACT
Piperacillin/tazobactam
(TZP)
is
administered
intravenously
in
a
fixed
ratio
(8:1)
with
the
potential
for
inadequate
tazobactam
exposure
to
ensure
piperacillin
activity
against
Enterobacterales
.
Adult
patients
receiving
continuous
infusion
(CI)
of
TZP
and
therapeutic
drug
monitoring
(TDM)
both
agents
were
evaluated.
Demographic
variables
other
pertinent
laboratory
data
collected
retrospectively.
A
population
pharmacokinetic
approach
was
used
select
best
kidney
function
model
predictive
clearance
(CL).
The
probability
target
attainment
(PTA),
cumulative
fraction
response
(CFR)
between
computed
identify
optimal
dosage
regimens
by
across
function.
This
study
included
257
critically
ill
(79.3%
male)
intra-abdominal,
bloodstream,
hospital-acquired
pneumonia
infections
89.5%
as
primary
indication.
median
(min-max
range)
age,
body
weight,
estimated
glomerular
filtration
rate
(eGFR)
66
(23–93)
years,
75
(39–310)
kg,
79.2
(6.4–234)
mL/min,
respectively.
Doses
up
22.5
g/day
optimize
based
on
TDM.
2021
chronic
disease
epidemiology
equation
mL/min
modeled
CL.
piperacillin:tazobactam
increased
from
6:1
10:1
an
eGFR
<20
>120
mL/min.
At
conventional
doses,
PTA
below
90%
when
≥100
Daily
doses
18
CI
are
expected
achieve
>80%
CFR
100–120
>120–160
Inadequate
likely
≥
100
Dose
regimen
adjustments
informed
TDM
should
be
evaluated
this
specific
population.
Antibiotics,
Journal Year:
2023,
Volume and Issue:
12(12), P. 1729 - 1729
Published: Dec. 14, 2023
Infections
caused
by
carbapenem-resistant
Acinetobacter
baumannii
(CRAB)
remain
a
clinical
challenge
due
to
limited
treatment
options.
Recently,
cefiderocol,
novel
siderophore
cephalosporin,
and
sulbactam-durlobactam,
bactericidal
β-lactam-β-lactamase
inhibitor
combination,
have
been
approved
the
Food
Drug
Administration
for
of
A.
infections.
In
this
review,
we
discuss
mechanisms
action
resistance
cefiderocol
antimicrobial
susceptibility
isolates
these
drugs,
as
well
effectiveness
sulbactam/durlobactam-based
regimens
against
CRAB.
Overall,
sulbactam-durlobactam
show
an
excellent
activity
The
review
studies
evaluating
efficacy
therapy
CRAB
indicates
it
is
non-inferior
colistin/other
treatments
infections,
with
better
safety
profile.
Combination
not
associated
improved
outcomes
compared
monotherapy.
Higher
mortality
rates
are
often
prior
patient
comorbidities
severity
underlying
infection.
Regarding
current
data
from
pivotal
trial
case
reports
suggest
antibiotic
combination
could
be
valuable
option
in
critically
ill
patients
affected
particular
where
no
other
appears
effective.
Frontiers in Microbiology,
Journal Year:
2024,
Volume and Issue:
15
Published: May 10, 2024
Gram-negative
bacteria
have
been
one
of
the
most
studied
classes
in
field
microbiology,
especially
context
globally
alarming
antimicrobial
resistance
levels
to
these
pathogens
over
course
past
decades.
With
high
numbers
microorganisms
being
described
as
multidrug-resistant
(MDR),
or
even
extended-drug-resistant
(XDR)
bacteria,
specialists
struggling
keep
up
with
higher
prevalence
difficult-to-treat
infections
caused
by
such
superbugs.
The
FDA
approval
novel
antimicrobials,
cefiderocol
(FDC),
ceftolozane/tazobactam
(C/T),
ceftazidime/avibactam
(CZA),
imipenem/relebactam
(IMR),
sulbactam/durlobactam
(SUL-DUR)
and
phase
3
clinical
trials’
results
aztreonam/avibactam
(ATM-AVI)
has
proven
that,
while
all
substances
provide
encouraging
efficacy
rates,
antibiotic
keeps
pace
drug
development.
Microorganisms
developed
more
extensive
mechanisms
order
target
threat
posed
thus
equiring
researchers
be
on
a
constant
lookout
for
other
potential
candidates
molecule
However,
strategies
require
proper
understanding
bacterial
gain
comprehensive
outlook
issue.
present
review
aims
highlight
six
agents,
which
brought
hope
clinicians
during
decade,
discussing
general
properties
substances,
well
patterns
resistance,
also
providing
short
overview
further
directions
field.
Systematic
registration
https://www.crd.york.ac.uk/prospero/#searchadvanced
,
Identifier
CRD42024505832.
